AssureCKD Team Publishes Breakthrough Microfluidic Immunoassay Research for Point-of-Care Kidney Screening
AssureCKD, a medical device company developing a lab-equivalent, point-of-care chronic kidney disease (CKD) screening and diagnostic device, is proud to announce the publication of its latest research in the peer-reviewed journal article “Integrated microfluidic immunoassays for point-of-care test system”. This breakthrough demonstrates significant advancement in delivering rapid, accurate, lab-grade CKD screening at the point of care.
The research details the development of an integrated microfluidic immunoassay platform designed to measure key kidney-function biomarkers including Cystatin C (Cys-C) in a compact, low-footprint device. In the study, the authors report that the microfluidic “paper-chip” test showed higher accuracy in determining estimated glomerular filtration rate (eGFR) ranges compared to conventional approaches.
For AssureCKD’s team, this publication marks a major milestone in fulfilling the company’s mission: to close the global health-system gap in kidney disease detection and empower pharmacies, clinics, and at-home care providers with a reliable rapid-test solution for early CKD detection.
Key Findings: Microfluidic Immunoassay Innovation for Early CKD Detection
The microfluidic immunoassay device integrates multiplexed detection of biomarkers on a paper-chip platform, enabling near-patient, point-of-care (POC) measurement of kidney function. ScienceDirect
The device achieved improved accuracy in stratifying patients by eGFR range, a critical metric in identifying early-stage CKD when interventions are most effective. ScienceDirect
The system is designed for ease-of-use outside traditional lab settings, aligning perfectly with AssureCKD’s B2B device + consumables model for clinics, pharmacies and home-care providers.
Why Early CKD Screening Technology Matters
Chronic kidney disease affects millions of individuals globally, often going undetected until advanced stages when treatment options become limited. Traditional diagnostics require lab visits, costly equipment and time-delays. By contrast, the new microfluidic immunoassay platform offers rapid, accurate, near-patient testing, bringing lab-grade analysis into community settings. For AssureCKD, this means enabling early intervention, reducing burden on healthcare systems and enabling better outcomes for patients.
“Publishing these results is a proud moment for our team,” said Claudio Rigatto with AssureCKD development team. “It reaffirms our vision to democratize kidney-health screening, and puts us one step closer to making that vision a reality.”
About AssureCKD
AssureCKD is developing MATLOC, a lab-equivalent diagnostic platform designed to screen, diagnose, and monitor chronic kidney disease at the point-of-care. By enabling rapid, accessible, and cost-effective testing in primary care and decentralized settings, AssureCKD aims to increase screening rates and facilitate earlier intervention, ultimately improving outcomes and reducing expensive healthcare costs.
